SAFETY DATA SHEET

Product Name: Vincristine Sulfate Injection, USP

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Names And Addresses	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA	Hospira Australia Pty Ltd 1 Lexia Place Mulgrave VIC 3170 AUSTRALIA
Emergency Telephone #'s	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418	
Hospira, Inc., Non-Emergency	224 212-2000	
Material Name	Vincristine Sulfate Injection, USP	
Synonyms	Leurocristine sulfate; Oncovin®	

2. HAZARD(S) IDENTIFICATION

Emergency Overview

Vincristine Sulfate Injection, USP is a solution containing vincristine sulfate, a salt of a vinca alkaloid that binds to microtubule proteins of the spindle, arresting cellular mitosis. Clinically, this product is used to treat some types of cancers. It is cytotoxic. In the workplace, this product should be considered very irritating to the skin, eyes, and respiratory tract, a potential occupational reproductive hazard, harmful to the fetus, and a potential human carcinogen. Based on clinical use, possible target organs may include the bone marrow, gastrointestinal system, nervous system, kidneys, skin, and gonads.

U.S. OSHA GHS Classification

	Hazard Class	**Hazard Category**
Physical Hazards	Not Classified	Not Classified
Health Hazards	**Hazard Class**	**Hazard Category**
	Toxic to Reproduction	2

Label Element(s)

Pictogram

Signal Word: Warning

Hazard Statement(s): Suspected of damaging fertility or the unborn child

Precautionary Statement(s)

Prevention

Obtain special instructions before use
Do not handle until all safety precautions have been read and understood
Wear protective gloves/protective clothing/eye protection/face protection
Do not breathe vapor or spray
Wash hands thoroughly after handling

Response

If exposed or concerned: Get medical advice/attention. Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Vincristine Sulfate
Chemical Formula $C_{46}H_{56}N_4O_{10} \cdot H_2SO_4$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Vincristine Sulfate	0.1	2068-78-2	OH6340000

Non-hazardous ingredients include Water for Injection and 10% mannitol. Hazardous ingredients present at less than 1% include sodium hydroxide and/or sulfuric acid which are added to adjust the pH.

4. FIRST AID MEASURES

Eye Contact Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Ingestion Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability None anticipated for this aqueous product.

Fire & Explosion Hazard None anticipated for this aqueous product.

Extinguishing Media As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.

Special Fire Fighting Procedures No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb liquid with suitable material and clean affected area with soap and water. An undiluted solution of household bleach may be applied to the spill area for ten minutes to further inactivate this material. Absorb the liquid with an inert absorbent material (e.g. absorbent pad). Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling Vincristine sulfate is a cytotoxic agent. Appropriate procedures should be implemented during the handling and disposal of cytotoxic antineoplastics agents to minimize potential exposures. Several guidelines on handling cytotoxic antineoplastic agents have been published. Consult your hygienist or safety professional for your site requirements.

7. HANDLING AND STORAGE: continued

Handling: continued

Avoid ingestion, inhalation, skin contact, and eye contact. When handling, precautions may include the use of a containment cabinet. The use of disposable gloves and respiratory protection is recommended. Proper disposal of contaminated vials, syringes, or other materials is required when working with this product.

Storage

No special storage is required for hazard control. However, employees should be trained on the proper storage procedures for antineoplastic agents. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions

Persons with known hypersensitivities to vincristine sulfate or other vinca alkaloids, women who are pregnant, or women who want to become pregnant, should consult a health and/or safety professional prior to handling open containers of this product.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

	Exposure Limits			
Component	**OSHA-PEL**	**ACGIH-TLV**	**AIHA WEEL**	**Hospira EEL**
Vincristine Sulfate	8-hr TWA: Not established	8-hr TWA: Not established	8-hr TWA: Not Established	8-hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
AIHA WEEL: Workplace Environmental Exposure Level
EEL: Employee Exposure Limit.
TWA: 8-hour Time Weighted Average.

Respiratory Protection

Respiratory protection is normally not needed during intended product use. However, if the generation of dusts or aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N99 or equivalent) is recommended under conditions where airborne dust or aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin Protection

When handling this product, disposable gloves should be worn at all times. Further, the use of double gloves is recommended. Disposable gloves made from nitrile, neoprene, polyurethane or natural latex generally have low permeability to this material. Persons known to be allergic to latex rubber should select a non-latex glove. Gloves should be changed regularly, and removed immediately after known contamination. Care should be taken to minimize inadvertent contamination when removing and/or disposing of gloves.

Eye Protection

As a minimum, the use of chemical safety goggles is recommended when handling this product.

Engineering Controls

Good local exhaust ventilation is recommended to minimize employee exposure. The use of an enclosure, such as an approved ventilated cabinet designed to minimize airborne exposures, is also recommended.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	A clear, colorless liquid in a vial
Odor	Odorless to faint vinegar-like odor
Odor Threshold	NA
pH	4.0 to 5.0
Melting point/Freezing Point	NA
Initial Boiling Point/Boiling Point Range	NA
Flash Point	NA
Evaporation Rate	NA
Flammability (solid, gas)	NA
Upper/Lower Flammability or Explosive Limits	NA
Vapor Pressure	NA
Vapor Density (Air =1)	NA
Relative Density	NA
Solubility	Soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol
Partition Coefficient: n-octanol/water	NA
Auto-ignition Temperature	NA
Decomposition Temperature	NA
Viscosity	NA

10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to Avoid	Not determined
Incompatibilities	Sensitive to hydrolysis, oxidation and heat. Incompatible with strong oxidizing agents.
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), and sulfur oxides (SOx).
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
*Vincristine Sulfate Injection	0.1	LD50	Oral	> 1000	mg/kg	Rabbit
*Vincristine Sulfate Injection	0.1	LD50	Dermal	> 1000	mg/kg	Rabbit
*Vincristine Sulfate	100	LC50(1hr)	Inhalation	> 1200	mg/m3	Rat
Vincristine Sulfate	100	LD50	Intravenous	1.0	mg/kg	Rat
Vincristine Sulfate	100	LD50	Intravenous	1.7	mg/kg	Mouse

LD50 is the dosage producing 50% mortality. *Eli Lilly and Company MSDS

Occupational Exposure Potential

There are scientific studies that suggest that personnel (e.g. nurses, pharmacists, etc.) who prepare and administer parenteral antineoplastics (e.g. in hospitals) may be at some risk due to potential mutagenicity, teratogenicity, and/or carcinogenicity of these materials if workplace exposures are not properly controlled. The actual risk in the workplace is not known.

Signs and Symptoms

None anticipated from normal handling of this product. Vincristine sulfate is irritating to the skin and mucous membranes and extravasation may cause necrosis, cellulitis, and sloughing. This material should also be considered very irritating to the eyes and respiratory tract. In clinical use, adverse effects may include bone-marrow depression, anorexia, nausea and vomiting, and central and peripheral neurotoxicity. Other adverse effects include headache, malaise, dizziness, skin reactions, alopecia, dyspnea and bronchospasm, and infertility. Aspermia in men and amenorrhea in women have been reported following treatment.

Aspiration Hazard

None anticipated from normal handling of this product.

Dermal Irritation/ Corrosion

None anticipated from normal handling of this product. Moderate skin irritation was noted when applied to the skin of rabbits as a dilute (9%) aqueous solution for 24 hours. Based on clinical use, this product may be irritating to the skin.

Ocular Irritation/ Corrosion

Irritant. This product has produced severe eye irritation and pitting of the cornea followed by healing. Occupational exposure during manufacturing and in clinical settings has produced severe irritation, tearing, pain, and blurred vision.

Dermal or Respiratory Sensitization

None anticipated from normal handling of this product. Rare instances of allergic reactions have occurred from clinical use of vincristine. No data on allergic sensitization potential from repeated skin contact were found.

Reproductive Effects

None anticipated from normal handling of this product. In clinical use, both male and female patients who received multiple–agent chemotherapy that included vincristine sulfate indicate that azoospermia and amenorrhea can occur in postpubertal patients.

When pregnant mice and hamsters were given doses of vincristine sulfate that caused resorption of 23% to 85% of fetuses, fetal malformations were produced in those that survived. Five monkeys were given single doses of vincristine sulfate between days 27 and 34 of their pregnancies; 3 of the fetuses were normal at term, and 2 viable fetuses had grossly evident malformations at term. In several animal species, vincristine sulfate can induce teratogenesis as well as embryo death at doses that are nontoxic to the pregnant animal.

Mutagenicity

Vincristine sulfate was not mutagenic *Salmonella typhimurium* with or without microsomal activation, produced no chromosomal aberrations in CHO cells or in a Syrian hamster fibroblast cell line, and failed to transform C3H/10T½ clone 8 cells. However, the drug did increase numerical and/or structural chromosomal aberrations in mouse bone-marrow cells and embryonic tissues. It also increased micronuclei formation in mouse bone-marrow cells and increased sister chromatid exchanges in a hamster cell line and human lymphocytes.

11. TOXICOLOGICAL INFORMATION: continued

Carcinogenicity	Vincristine sulfate was negative in one cancer study in rats and mice although the study was limited. Some patients who received chemotherapy with vincristine in combination with anti-cancer drugs known to be carcinogenic have developed second malignancies.
Carcinogen Lists:	**IARC:** Group 3 - not classifiable **NTP:** Not listed **OSHA:** Not listed
Specific Target Organ Toxicity – Single Exposure	NA
Specific Target Organ Toxicity – Repeat Exposure	Based on clinical use, possible target organs may include the bone marrow, gastrointestinal system, nervous system, kidneys, skin, and gonads.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product. Vincristine is not considered readily biodegradable; it degraded about 30% in a 28-day biodegradation assay.
Bioaccumulation	Not determined for product.
Mobility in Soil	Not determined for product.

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
ICAO/IATA STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
IMDG STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

US TSCA Status	Exempt
US CERCLA Status	Not listed
US SARA 302 Status	Not listed
US SARA 313 Status	Not listed
US RCRA Status	Not listed
US PROP 65 (Calif.)	This product is, or contains chemical(s) known to the State of California to cause developmental toxicity.

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification*

*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA

Prevention

Obtain special instructions before use
Do not handle until all safety precautions have been read and understood
Wear protective gloves/protective clothing/eye protection/face protection
Do not breathe vapor or spray
Wash hands thoroughly after handling

Response

If exposed or concerned: Get medical advice/attention. Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

EU Classification*

*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.

Classification(s)	NA
Symbol	NA
Indication of Danger	NA
Risk Phrases	NA
Safety Phrases	S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD_{50}	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: October 19, 2012
Date Revised: June 02, 2014

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.